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We investigated the discrepancy between the broad cross-protection against gram-negative
infections afforded by antiserum to Escherichia coli J5 and its apparently narrow cross-
reactivity in vitro. Rabbits immunized with J5 bacteria produced antibodies to both the
J5 lipopolysaccharide (LPS; titer by ELISA, 1:60,0(0) and LPS from the Re mutant of
Salmonella minnesota (i.e., to the ketodeoxyoctonate [KDO] and lipid A determinants;
titer, 1:3,2(0). In highly diluted antiserum, titers of antibody to J 5 LPS were reduced
by 28070-41% after adsorption with seven strains of smooth gram-negative bacteria and
by only 4% after adsorption with the Re mutant. Smooth gram-negative bacteria adsorbed
virtually all antibody to Re LPS. Therefore, rabbit antiserum to J 5 contains type-specific
antibodies to core determinants distal to KDO that can obscure highly cross-reactive anti-
bodies to lipid A-KDO in vitro. Cross-reactive antibodies are demonstrable byadsorp-
tion with whole bacteria at limiting concentrations of antibody.
Endotoxins (lipopolysaccharides [LPS)) from rough
mutants contain lipid A (the toxic moiety of the mol-
ecule) and some sugars from the core region, but,
in contrast to LPS from smooth bacteria, they lack
the very immunogenic oligosaccharide side chains
[1,2]. Although these 0 side chains exhibit wide an-
tigenic variation, the LPS core region is conserved
among gram-negative bacteria. Immunizing animals
with smooth gram-negative bacteria does not stimu-
late the formation of cross-protective antibody, de-
spite the fact that LPS from these smooth bacteria
also contain the common determinants of core LPS.
This observation has been explained by either steric
hindrance (because the core LPS is surrounded by
side chains) or poor immunogenicity of core LPS
compared with the immunogenic dominance of side
chains.
Immunization with LPS from rough mutants
stimulates high titers of antibody to determinants
of LPS core, and the potential of such antisera to
protect against a wide variety of unrelated, smooth
gram-negative bacteria or endotoxins (LPS) has been
established in numerous experimental models [3-13].
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Clinical studies have shown that antiserum to Esch-
erichia coli J5 increased the survival of patients who
had gram-negative bacteremia [14] and prevented
shock due to gram-negative infections in high-risk
surgical patients [15].
Antisera raised to rough mutants have cross-
protective activity that we and others have attributed
to the presence of antibodies to core LPS [1, 11, 16],
but cross-reaction between antibody to rough mu-
tants and smooth gram-negative bacteria has been
difficult to demonstrate in vitro. Immunofluorescent
tests using whole smooth bacteria as antigens sug-
gested the existence of cross-reactive antibodies be-
cause adsorption of antiserum to the Re mutant of
Salmonella minnesota with Re LPS eliminated stain-
ing [17, 18].However, other attempts in which puri-
fied LPS was used as the antigen in direct or indirect
HA tests, complement-dependent hemolysis assays,
precipitin tests in agar gel, RIAs, ELISAs, and im-
munoblot assays have revealed little cross-reactive
antibody in antisera to rough mutants [19-23 and
unpublished observations from the laboratory of
E. J. Z. and the late Dr. A. I. Braude.] The dis-
crepancy between the cross-protection observed in
animal models and humans and the poor in vitro
cross-reactivity of antisera has prompted many to
question whether antibody is the protective factor
in antiserum to J5. In this paper we show that anti-
body cross-reactive with smooth gram-negative bac-
teria can be demonstrated by a sensitive ELISA.
Antiserum to E. coli J5
Materials and Methods
Bacteria. All bacteria were standard strains from
our laboratory, except for the R mutants of S. min-
nesota (gifts from Dr. O. Luderitz, Max Planck In-
stitut fur Immunobiologie, Freiburg, FRO). The iso-
lates were stored on trypticase soy agar (TSB; Difco,
Detroit). For the adsorption experiments, the bac-
teria were grown overnight at 37 C in TSB, harvested
by centrifugation, washed three times in 0.15 M
NaCI, and boiled for 2.5 hr.
LPS. LPS was extracted from rough mutants of
S. minnesota Re595 or E. coli J5 by using the phenol-
chloroform-petroleum ether method of Oalanos et
al. [24] and from smooth strains (clinical isolates)
by the phenol-water method of Westphal et al. [25].
Antisera. Boiled bacterial cells were suspended
in 0.15MNaCI and adjusted spectrophotometrically
to a concentration of 109 cells/ml (22070 light trans-
mission at 610 nm). New Zealand white rabbits
weighing 1.5-2.0 kg were immunized with six iv in-
jections of 1 m1 of boiled cells administered during
a two-week period. Samples of blood were collected
seven days after the last injection and were allowed
to clot. The serum was separated by centrifugation,
pooled, and stored aseptically at 4 C. Each sample
of antiserum was a pool from at least two immunized
rabbits.
ELISA. We used 96-well,polyvinyl tissue culture
plates (Costar, Cambridge, Mass). The peripheral
wells were not used because we had previously de-
tected consistent artifacts in reactions in them. Be-
tween each step, the wells were washed three times
(five times for the last step) with PBS (pH 7.2). Poly-
L-Iysine (Me, 90,000; Sigma, St. Louis) was diluted
to 10 ug/rnl in PBS, and 50 ul was added to each
well and allowed to incubate for 30 min at room tem-
perature. This procedure improved the adherence of
LPS to the plastic wells and decreased the back-
ground OD (D. Morrison, personal communication).
After washing the wells, we added 100 ul of LPS
(diluted to 8 ug/ml in PBS) and incubated them over-
night at 4 C. After another washing, the wells were
filled with 150 ul of 10070 horse serum in PBS (horse
serum buffer). The wells were washed after incuba-
tion for 1 hr, and lOO-~1 aliquots of rabbit serum
diluted in horse serum buffer were added in quadru-
plicate to the wells. The wells were washed after in-
cubating for 1 hr at 37 C, and 100 ul of horseradish
peroxidase-conjugated goat antibody to rabbit im-
munoglobulins (Sigma), diluted 1:1,000in horse se-
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rum buffer, was added to each well and incubated
for 1 hr at 37 C. Peroxidase substrate buffer (90 ml
of H20, 5 ml of 1.0 M citric acid, 5 ml of 1.0 M so-
dium citrate, 0.33 ml of 3070 H202 , and 50 ml of 0-
phenylenediamine [Sigma]) was prepared immedi-
ately before use, and 150 ul was added to each well.
The reaction was stopped after 1 hr at room tem-
perature by adding 40 ul of 4 N H2S04/well. The
OD was read at 490 nm by using a photometer (Dy-
natech, Chantilly, Va), The titer was defined as the
highest dilution yielding an OD of 0.15.
Adsorption ofantisera. Twofold serial dilutions
of rabbit antisera were tested by ELISA to determine
the titration curve for each antibody. The dilution
yielding an OD at the middle part of the sigmoidal
titration curve was used for the adsorption experi-
ments. All aliquots (for adsorptions and for controls)
were taken from the same batch of antisera diluted
in horse serum broth. For adsorptions with bacte-
ria, 1.0 ml of sera diluted in horse serum broth was
added to 50-100 ul of centrifuged bacteria, mixed,
and incubated overnight at 4 C. For adsorption with
purified LPS, 200 ul of a 1 mg/ml solution of LPS
was added to 1.0 ml of diluted sera. The same vol-
ume of horse serum broth was added for the con-
trol. We used 200 ul of either washed, packed human
type 0 erythrocytes or Sephadexf 010 (Pharmacia,
Piscataway, NJ) as controls for nonspecific adsorp-
tion by particles. The sera were then recovered by
centrifugation, and the titers of remaining antibody
were measured by ELISA. All adsorptions in each
experiment were performed the same day.
Statistics. We used analysis of variance
(ANOVA) to test the differences between the mean
ODs of the experimental groups. When the null hy-
pothesis was rejected by ANOVA, we used the Tukey
test for multiple comparison to determine which
differences were significant [26].
Results
Titers ofantibody in antisera to LPSfrom rough
bacteria. Table 1 shows the titers of antibody to
LPS in antisera from rabbits immunized with vari-
ous bacteria. Immunizing rabbits with E. coli 0111
did not elicit antibodies to LPS from rough bacte-
ria, with the exception of a modest antibody response
to the Re core. As expected, the titers of antibody
were highest against the homologous LPS from
rough bacteria. The only exception was that the titers
of antibody to Re LPS were higher in antisera from
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Table 1. Titers of antibody to LPS in antisera from rabbits immunized with various bacteria.
Organism used
Reciprocal titers of antibody to
for vaccination J5 LPS Ra LPS RcLPS Re LPS 0111 LPS
Control (saline) <100 200 <100 200 <100
E. coli 0111 <100 <100 <100 400 25,600
J5 mutant" 60,000 200 3,200 3,200 1,600
S. minnesota
Ra mutant 400 10,000 1,600 3,200 200
Rc mutant 400 400 3,200 200 <100
Re mutant 200 200 200 800 100
NOTE. The titer was defined as the highest dilution yielding an 00 of 0.15.
• The J5 mutant of E. coli 0111 is the equivalent of the Rc mutant of S. minnesota.
rabbits immunized with the Ra mutant (antiserum
to Ra) and the J5 mutant (antiserum to J5) than in
antiserum of rabbits immunized with the Re mutant
itself (antiserum to Re), perhaps because of the rel-
atively low immunogenicity of the Re mutant. There
were widely different antibody responses between an-
tisera to various rough mutants. Antiserum to J5 be-
haved differently from antiserum to Rc. Whereas an-
tisera to J5 and to Rc had similar titers of antibody
to Rc LPS (1 :3,200), antiserum to Rc had a much
lower titer of antibody to J 5 LPS (l :400) than did
antiserum to J5 (l :60,000), a result suggesting that
J 5 LPS might possess antigenic determinants that
are not present on Rc LPS. In fact, N-acetylglu-
cosamine has been found in the distal J5 core and
not in the Rc core [1, 2]. These (and other) chemical
differences in the composition of the core sugar or
lipid A might explain the variety of antibody re-
sponses. It is thus clear that the most easily detect-
able antibodies in antisera to LPS from rough mu-
tants are type-specific.
Adsorption of antiserum to J5 with purified
LPS. In two experiments, adsorption of antiserum
to J5 (diluted 1:10,000) with LPS from smooth bac-
teria produced only a small decrease in titer of anti-
body to J5 LPS (table 2). To find out if antibody
to core LPS in antiserum to J5 bound to LPS from
smooth bacteria, we measured in vitro antibody
binding to LPS from smooth bacteria before and af-
ter adsorption with J5 LPS.
Much to our surprise, after adsorption with J5
LPS, there was a several-fold increase in titer of an-
tibody to LPS from smooth bacteria (table 3). This
result raises the possibility that J5 LPS-antibody
complexes remained in the antisera despite the cen-
trifugation step and were subsequently adsorbed
Table 2. Antibodies to J5 LPS in rabbit antiserum to E. coli J5: adsorption with purified LPS.
Antibodies to J5 LPS
First experiment Second experiment
LPS used
for adsorption 00 (SO)
Decrease in 00 (070)
after adsorption 00 (SO)
Decrease in 00 (%)
after adsorption
No adsorption"
Klebsiella pneumoniae
E. coli 04
Salmonella typhimurium
E. coli 0113
Serratia marcescens
E. coli 0111
Rough mutant of E. coli 0113t
E. coli J5
0.724 (0.021) 0.591 (0.032)
0.681 (0.042) 6 0.513 (0.025) 14
0.658 (0.003) 9 0.470 (0.014) 21
0.647 (0.20) 11 0.544 (0.027) 8
0.635 (0.001) 12 0.503 (0.029) 15
0.620 (0.001) 14 0.543 (0.028) 8
0.584 (0.013) 19 0.517 (0.019) 13
0.209 (0.008) 71 0.138 (0.005) 77
0.107 (0.003) 85 0.066 (0.004) 89
NOTE. The 00 values are the mean of four readings; the background values (from wells with nonimmune serum) have already
been subtracted (mean 00 [SOl, 0.02 [0.(02)). The dilution of antiserum to J5 was 1:10,000.
• A volume of horse serum buffer similar to that of soluble LPS was added to the serum.
t Re-type mutant of E. coli 0113.
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Table 4. Effect of dilution on antibody to J5 LPS in
rabbit antiserum to E. coli J5
of antibody to 15 LPS, whereas adsorption with the
homologous 15 mutant did. Adsorption of antiserum
to 15 (diluted 1:6,4(0) with E. coli 0111 decreased
the titer of antibody to 15 LPS only slightly. From
these results we concluded that it was necessary to
use highly diluted antiserum to demonstrate that ad-
sorption with smooth gram-negative bacteria de-
creased the titer of antibody to 15 LPS. Therefore,
we used dilutions of antisera yielding one-half of the
maximal Of) values.
When 15 LPS was used as an antigen on ELISA
plates, adsorption of antiserum to 15 (diluted
1:10,000) with smooth gram-negative bacteria sig-
nificantly lowered (by 28070-41070) the aD values,
compared with those of unadsorbed controls or se-
rum adsorbed with gram-positive Bacillus subtilis
(P < .001; table 5). Adsorption by the Rc mutant
Of) of antibody to 15 in
antiserum to 15
Table 3. Antibodies to Ra LPS, E. coli 04 LPS, and
Pseudomonas aeruginosa LPS in rabbit antiserum to
E. coli J5: adsorption with various antigens.
Titer of indicated antibody in
antiserum to J 5
Antibody Antibody to
Antigens used Antibody to to E. coli P. aeruginosa
for adsorption Ra LPS 04 LPS LPS
B. subtilis 0.22* 0.20 0.16
E. coli J5 0.22 0.15 0.16
15 LPS 1.89 0.59 1.32
Homologous
bacteria 0.18 0.10 0.11
Homologous LPS 0.22 0.07 0.13
NOTE. The dilution of antiserum to 15 was 1:20.
* Mean of 2 Ol) values.
onto the ELISA plates. This artifact is an interest-
ing phenomenon with general application, and it
should be investigated further. Because we did not
observe it when whole 15 bacteria were used instead
of purified LPS (table 3), we decided to perform all
further adsorption experiments with whole bacte-
ria instead of LPS.
Adsorption ofantisera to J5 and Re with whole
bacterial cells. Preliminary experiments (table 4)
demonstrated that adsorption of antiserum to 15,
diluted 1:400 with E. coli 0111 (the smooth parent
of the 15 mutant), did not perceptibly lower the titer
Bacteria used
for adsorption
None
E. coli 0111
E. coli 15
Experiment 1
(1:400 dilution)
> 1.55
> 1.55
0.15
Experiment 2
(1:6,400 dilution)
> 1.55
1.48
0.037
Table 5. Antibodies to J5 LPS and Re LPS in rabbit antiserum to E. coli J5: adsorption with various bacteria.
Level of indicated antibody in antiserum to 15
Bacteria used
for adsorption on (SD)
Antibody to 15 LPS
Decrease in Of) (010)
after adsorption on (SD)
Antibody to Re LPS
Decrease in on (%)
after adsorption
No adsorption
B. subti/is
Re mutant
S. minnesota
P. aeruginosa
S. marcescens
K. pneumoniae
Ra mutant
E. coli 0111
E. coli 017
Rc mutant
15 mutant
0.99 (0.028)
0.98 (0.043)
0.95 (0.076)
0.71 (0.029)
0.69 (0.026)
0.68 (0.036)
0.65 (0.009)
0.63 (0.008)
0.63 (0.039)
0.58 (0.027)
0.50 (0.044)
0.03 (0.003)
1
4
28
30
31
34
36
36
41
49
97
0.88 (0.037)
0.53 (0.043)
0.09 (0.021)
0.02 (0.025)
0.01 (0.031)
0.06 (0.006)
0.11 (0.018)
0.11 (0.031)
0.05 (0.006)
0.08 (0.018)
0.10 (0.049)
0.26 (0.012)
39
90
98
99
93
88
88
94
91
89
70
NOTE. The antiserum to 15 was diluted 1:10,000 to measure antibody to 15 LPS and 1:400 to measure antibody to Re LPS.
* The Of) values are the mean of four values. The mean Of) values for un adsorbed sera were standardized to 1.00, and then
the background Ol) was subtracted; the same standardization was applied to the other Of) values. (The mean background Of) [SD]
was 0.01 [0.003] for the plates with 15 LPS and 0.12 [0.018] for the plates with Re LPS.)
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Table 6. Antibody to Re LPS in rabbit antiserum to
E. coli J5: adsorption with various bacteria.
NOTE. The antiserum to Re was diluted 1:400.
* Mean of four values after subtraction of the background
(mean OD [SDl, 0.06 [0.013]).
organisms also adsorbed antibodies slightly (decrease
of 10070-30070 of OD values). Smooth gram-negative
bacteria, however, removed most of the antibody to
Re LPS from the antiserum (66070-93010, P < .05
compared with the results of adsorptions with gram-
positive organisms). Therefore, in another system,
antibodies to lipid A-KDO are cross-reactive with
smooth gram-negative bacteria.
22
65
74
74
78
83
83
91
96
96
100
Decrease in OD (010)
after adsorptionOD* (SD)
Antibody to Re LPS
0.23 (0.018)
0.18 (0.028)
0.08 (0.020)
0.06 (0.016)
0.06 (0.029)
0.05 (0.012)
0.04 (0.009)
0.04 (0.009)
0.02 (0.019)
0.01 (0.002)
0.01 (0.010)
0.00 (0.008)
No adsorption
B. subtilis
E. coli 017
E. coli 0111
J5 mutant
K. pneumoniae
S. marcescens
Ra mutant
Rc mutant
S. minnesota
P. aeruginosa
Re mutant
We and others have contended that the mechanism
of protection afforded by antiserum to J5 or plasma
to J5 in preventing septic shock involves neutraliza-
tion of the harmful effects of endotoxins by means
of cross-reactive antibodies to the determinants of
core LPS. Three different lines of argument favor
this hypothesis. First, retrospective studies in humans
have reported a significant correlation between titers
of antibody to core LPS and survival of patients with
gram-negative bacteremia due to many different or-
ganisms [27, 28]. This correlation was independent
of the titers of strain-specific antibodies and sug-
gested therefore that antibody to core LPS can pro-
tect patients from severe septic shock or death due
to gram-negative bacteria. Second, in a controlled,
prospective clinical study, plasma to J5 prevented
septic shock and death due to gram-negative, but not
gram-positive, organisms [15]; therefore, the cross-
protection was specific for gram-negative bacteria.
Bacteria used
for adsorption
decreased the OD value by 49070, a value signifi-
cantly less than the 97070 adsorption by the J5 mu-
tant (P < .001); this result also suggests that J5 LPS
must have antigenic determinants not available on Rc
LPS. There was essentially no decrease in antibody
binding after adsorption by the Re mutant, whose
LPS contains only lipid A and ketodeoxyoctonate
(KDO), a result suggesting that antibodies to the lipid
A-KDO region represent only a minor fraction of the
overall antibodies to J5 LPS in rabbit antiserum to
J5. Therefore, it can be deduced that the antibodies
to J5 LPS that were removed by incubation with un-
related, smooth gram-negative bacteria were directed
against distal determinants of the core sugar rather
than against the lipid A-KDO region.
When Re LPS was used as the coating antigen, the
titer of antibody in antiserum to J5 (1 :3,200) was
much lower than the titer of antibody to J5 LPS
(l :60,()()(); table 1). Therefore, we used serum diluted
1:400 for the adsorption experiments. Adsorption
with smooth gram-negative bacteria was as effective
as adsorption with rough mutants (table 5). This ob-
servation is strong evidence of the cross-reactive na-
ture of these antibodies to the lipid A-KDO region.
Adsorption by B. subtilis produced a decrease of 39010
in the.OD value. We also observed a similar decrease
in OD after adsorption with other gram-positive bac-
teria such as Streptococcus faecalis and Staphylococ-
cus epidermidis (53070 and 39010 decrease, respectively)
and with Candida albicans (21070 decrease). This re-
sult might have been due to nonspecific adsorption
by the gram-positive bacteria. However, nonspecific
adsorption seems an unlikely explanation because ad-
sorption with two nonspecific particulate controls
(washed, packed erythrocytes and Sephadex G10)had
absolutely no effect on the titers of antibody to J5
LPS or to Re LPS in antiserum to J5 or on titers of
antibody to Re in antiserum to Re (data not shown).
It is more likely that the decreased titers of antibody
after adsorption with gram-positive bacteria weredue
to the presence of determinants on the cell wall of
gram-positive bacteria; such determinants would
cross-react with antibodies to lipid A-KDO. These
results with gram-positive bacteria were significantly
lower than those obtained after adsorption with
smooth gram-negative bacteria (P < .05).
To find out if antibodies to the lipid A-KDO re-
gion in antiserum to Re behaved similarly, we sub-
jected antiserum to Re to the same battery of ad-
sorptions (table 6). The working dilution of
antiserum to Re was also 1:400. The gram-positive
Antiserum to E. coli J5
Third, the hypothesis of protective antibody to core
LPS is supported by previous animal experiments
showing cross-protection from antiserum to J5 not
only against whole gram-negative bacteria, but also
against purified endotoxins [3-13]. This suggests
that if a cross-reactive antibody is involved in the
protection afforded by antiserum to J5, it is prob-
ably directed against determinants of LPS and not
against other cell wall determinants on the gram-
negative bacteria. Because common LPS epitopes
are found only in the core portion of LPS, it seems
reasonable to postulate that cross-protectiveantibod-
ies are directed against these determinants. Some in-
vestigators have suggested that cross-protection is
due to activation of polyclonal B cells by rough LPS
with accompanying production of antibodies. Al-
though we cannot exclude this possibility altogether,
immunization with smooth gram-negative bacteria
(which also are polyclonal stimulators) does not re-
sult in cross-protective antiserum [3-13]; therefore,
polyclonal activation is unlikely to explain pro-
tection.
The idea that cross-protection is due to antibody
to core LPS has been questioned because cross-
reaction with LPS from smooth bacteria or with
gram-negative bacteria has been extremely difficult
for us and some others to demonstrate in vitro
[17-23]. Moreover, in two successful clinical trials
that clearly showed the effectiveness of administer-
ing antiserum to J5 or plasma to J5, the relation be-
tween the amount of measured antibody to J5 LPS
given to the patients and an improved outcome was
not strong [14, 15].
In the present study, we have addressed these dis-
crepancies. We have found wide variations in titers
of antibody to Ra, Rc, Re, and J5 LPS (as measured
byELISA) after immunizing rabbits with these rough
mutants. Therefore, the rough mutants seem to vary
considerably in their immunogenicity. Furthermore,
we have found that the majority of these antibodies
are type-specific for the LPS from the immunizing
rough mutant. A similar conclusion has also been
drawn from experiments using IHA to measure an-
tibody to LPS from rough bacteria [29]. To improve
the detection of cross-reactive antibodies in poly-
clonal antisera, we have used several techniques. Ad-
sorption with whole bacteria detects binding to LPS
in its most natural conformation. Furthermore, when
detecting antibodies of different binding specifici-
ties that are present in widely varying concentrations,
different dilutions of antibodies are required. For ex-
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ample, antibodies to J5 LPS are detectable at dilu-
tions as high as 1:60,000. In the same serum, anti-
bodies to Re LPS are detectable at 1:3,200. When
we used dilutions that yielded one-half of the maxi-
mum OD values, adsorption of the antibody to J5
LPS with various smooth gram-negative bacteria re-
vealed a definite but modest amount of cross-
reactivity. On the other hand, adsorption of anti-
body to Re LPS in the same serum revealed very
strong cross-reactions. Although we cannot prove
that adsorption by gram-positive bacteria was spe-
cific, the fact that this phenomenon was not observed
with nonspecific adsorbents or in the highly diluted
antiserum assayed against J5 LPS suggests that this
reaction was specific. Therefore, we suspect that an-
tibodies to Re LPS cross-react with some cell wall
determinants (such as glucosamine epitopes) that are
shared by peptidoglycan in gram-positive organisms
and by LPS core in gram-negative organisms.
In a recent study, Siber et at. [22] were not able
to demonstrate cross-reactive antibody to core LPS
in antisera of rabbits immunized with LPS from
rough mutants. These authors used ELISA tests and
adsorption experiments with soluble LPS, LPS
linked to outer membrane vesicles, and whole, gram-
negative bacteria. Their results might be explained
by the fact that they used antisera diluted only 1:25.
At this dilution, ELISAs using the whole molecule
of LPS from J 5 as a coating antigen detect mainly
strain-specific antibodies in polyclonal antiserum to
J5. The recent immunoblotting study by de Jongh-
Leuvenink et al. [23] used undiluted antiserum to
J5 for adsorption. They found some evidence of
cross-reactivity with core LPS from E. coli and from
S. typhimurium Re, but none with core LPS from
smooth gram-negative strains. The same technical
problem may also explain the difficulty in correlat-
ing clinical outcome with titers of antibody to J5 LPS
in our own clinical trials [14, 15].
The finding that antiserum to J5 contains highly
cross-reactive antibody to Re LPS is consistent with
results we and others have obtained by using mono-
clonal antibodies. Several groups have reported
highly cross-reactive monoclonal antibodies specific
for the lipid A-KDO region of the LPS molecule
[30-33]. Others have reported that antibodies to the
core polysaccharide distal to KDO are poorly cross-
reactive [34, 35, and authors' unpublished observa-
tions].
Polyclonal antisera to J5 LPS from the rough mu-
tant clearly contain considerable amounts (detect-
142
able at a dilution of 1:10,000) of antibody that is
cross-reactive with smooth gram-negative bacteria.
In vitro assays such as ELISAs are highly influenced
by antibody-binding characteristics. Differences in
antibody-binding characteristics between type-
specific and cross-reactive antibodies to J5 LPS may
account for the difficulties in demonstrating cross-
reactivity with smooth gram-negative bacteria in an-
tiserum to J5. Adsorption studies done at limiting
concentrations of antibody are more sensitive in de-
tecting cross-reactive binding than are adsorption ex-
periments performed with an excess of antibody. We
speculate that our assay requires limiting concentra-
tions of antibody to detect cross-reactive, but not
type-specific, antibody because the avidity of the an-
tibody binding to smooth gram-negative bacteria is
lower than the avidity of the antibody binding to J5
bacteria. The mechanistic implications of such bind-
ing are beyond the scope of this paper. We merely
wish to present a way in which cross-reactive anti-
bodies to smooth bacteria can be demonstrated eas-
ily and consistently in polyclonal antisera to LPS
from rough mutants.
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